Literature DB >> 24209763

Clinical trials for negative symptoms--emerging directions and unresolved issues.

Stephen R Marder1, Jonathan Rabinowitz, Shitij Kapur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24209763     DOI： 10.1016/j.schres.2013.10.005

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  4 in total

1.  A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS.

Authors:  Adrian Preda; Dana D Nguyen; Juan R Bustillo; Aysenil Belger; Daniel S O'Leary; Sarah McEwen; Shichun Ling; Lawrence Faziola; Daniel H Mathalon; Judith M Ford; Steven G Potkin; Theo G M van Erp
Journal:  Schizophr Res       Date:  2018-06-20       Impact factor: 4.939

2.  Cross Cultural Validation and Extension of the Clinical Assessment Interview for Negative Symptoms (CAINS) in the Chinese Context: Evidence from a Spectrum Perspective.

Authors:  Dong-Jie Xie; Hai-Song Shi; Simon S Y Lui; Chuan Shi; Ying Li; Karen K Y Ho; Karen S Y Hung; Wen-Xiu Li; Zheng-Hui Yi; Eric F C Cheung; Ann M Kring; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

3.  Validation of the Chinese version of the Clinical Assessment Interview for Negative Symptoms (CAINS): a preliminary report.

Authors:  Raymond C K Chan; Chuan Shi; Simon S Y Lui; Karen K Y Ho; Karen S Y Hung; Joanna W S Lam; Ya Wang; Eric F C Cheung; Xin Yu
Journal:  Front Psychol       Date:  2015-02-02

4.  The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study.

Authors:  Elmars Rancans; Zsófia Borbála Dombi; Péter Mátrai; Ágota Barabássy; Barbara Sebe; Iveta Skrivele; György Németh
Journal:  Int Clin Psychopharmacol       Date:  2021-05-01       Impact factor: 2.023
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.